Neurofilament in clinical practice: Is the multiple sclerosis community ready?

Arslan B Zetterberg H . Neurofilament light chain as neuronal injury marker – What is needed to facilitate implementation in clinical laboratory practice? Clin Chem Lab Med 2023; 61: 1140–1149.

Thebault S Bose G Booth R , et al. Serum neurofilament light in MS: The first true blood-based biomarker. Mult Scler 2022; 28(10): 1491–1497.

Consortium of Multiple Sclerosis Centers Neurofilament Consensus Paper. Neurofilament biomarkers in multiple sclerosis. CMSC best practices for the use of serum neurofilament (sNfL) in MS management, 2024, https://mscare.sharefile.com/d-s60a6a95b73684d83873c6d9cab9d66b8

Gaetani L Blennow K Calabresi P , et al. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psych 2019; 90(8): 870–881.

Bjornevik K Munger KL Cortese M , et al. Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis. JAMA Neurol 2020; 77: 58–64.

Marrie RA Allegretta M Barcellos LF , et al. From the prodromal stage of multiple sclerosis to disease prevention. Nat Rev Neurol 2022; 18(9): 559–572.

Kuhle J Plattner K Bestwick JP , et al. A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult Scler 2013; 19(12): 1597–1603.

Arrambide G Espejo C Eixarch H , et al. Neurofilament light chain level is a weak risk factor for the development of MS. Neurology 2016; 87: 1076–1084.

Bittner S Steffen F Uphaus T , et al. Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. eBiomedicine 2020; 56: 102807–102813.

Abdelhak A Benkert P Schaedelin S , et al. Neurofilament light chain elevation and disability progression in multiple sclerosis. JAMA Neurol 2023; 80: 1317–1325.

Brune S Høgestøl EA de Rodez Benavent SA , et al. Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis. Mult Scler 2022; 28(12): 1859–1870.

Williams T Tur C Eshaghi A , et al. Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial. Mult Scler 2022; 28(12): 1913–1926.

Barro C Healy BC Liu Y , et al. Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2023; 10(1): e200052.

Fissolo N Benkert P Sastre-Garriga J , et al. Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. Epub ahead of print 8 November 2023. DOI: 10.1136/jnnp-2023-332251.

Monreal E Fernández-Velasco JI García-Sánchez MI , et al. Association of serum neurofilament light chain levels at disease onset with disability worsening in patients with a first demyelinating multiple sclerosis event not treated with high-efficacy drugs. JAMA Neurol 2023; 80: 397–403.

Bose G Healy BC Barro C , et al. Accuracy of serum neurofilament light to identify contrast-enhancing lesions in multiple sclerosis. Mult Scler 2023; 29(11–12): 1418–1427.

Kuhle J Chitnis T Banwell B , et al. Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial. Mult Scler J 2023; 29: 385–394.

Foley J Xiong K Hoyt T , et al. Serum neurofilament light levels in natalizumab-treated patients with multiple sclerosis who switch to extended interval dosing from every-4-week dosing in real-world clinical practice. Mult Scler 2023; 29(2): 196–205.

Benkert P Meier S Schaedelin S , et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: A retrospective modelling and validation study. Lancet Neurol 2022; 21(3): 246–257.

Johnsson M Stenberg Y Farman H , et al. Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: A 48-week prospective single-center study. Mult Scler. Epub ahead of print 13 March 2024. DOI: 10.1177/13524585241237388.

Beydoun MA Noren Hooten N Maldonado AI , et al. BMI and allostatic load are directly associated with longitudinal increase in plasma neurofilament light among urban middle-aged adults. J Nutr 2022; 152: 535–549.

Fitzgerald KC Sotirchos ES Smith MD , et al. Contributors to serum NfL levels in people without neurologic disease. Ann Neurol 2022; 92(4): 688–698.

Sotirchos ES Hu C Smith MD , et al. Agreement between published reference resources for neurofilament light chain levels in people with multiple sclerosis. Neurology 2023; 101: e2448–e2453.